Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Precision oncology offers targeted treatments but requires robust cohort data.
• Previous work established a prospective experience in solid tumors.
• This study details the longitudinal therapeutic impact of precision oncology.

Purpose of the Study:

• To evaluate the therapeutic impact and overall survival (OS) outcomes in patients with incurable solid tumors undergoing precision oncology.
• To analyze the utilization and effectiveness of genomics-driven therapy versus non-genomics-driven treatment.

Main Methods:

• Retrospective review of 600 patients with incurable solid tumors treated between 2013-2016.
• Tumor genomic profiling performed using FoundationOne, with results discussed at a multidisciplinary genomics tumor board.
• Analysis of subsequent therapies and overall survival (OS) based on genomic profiling results.

Main Results:

• Targeted therapy was recommended for 51.7% of patients.
• Genomics-driven therapy (G) was administered to 15.8% of patients, while 36.4% received non-genomics-driven treatment (NG).
• Median OS was significantly longer for patients receiving G (18 months) and NG (14.4 months) compared to no therapy (5.5 months), with a trend favoring G.

Conclusions:

• Tumor genomic profiling influenced treatment decisions in 15.8% of patients.
• A higher proportion of patients in the G cohort received treatment via clinical trials.
• While not statistically significant, a trend toward increased OS was observed in the genomics-driven therapy group, supporting its role in real-world precision oncology.